Top Markets
#1 龙虾 (Lobster) 龙虾 (Lobster) +34.12%
#2 Cortex Cortex +31.95%
#3 DexNet DexNet +23.19%
#4 Akedo Akedo +21.42%
#5 Pons Pons +17.60%
#6 wojak wojak +15.79%
#7 OpenEden OpenEden +15.43%
#8 APEX APEX +13.93%
#9 TDCCP TDCCP +11.17%
#10 MANTRA MANTRA +10.66%
Coin of the day
龙虾 (Lobster) 龙虾 (Lobster)
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
HBM Holdings Limited HBM Holdings Limited

HBM Holdings Limited

2142
Classement en actions #7297
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused... HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
Prix de l'action
$1.95
Capitalisation boursière
$1.64B
Changement (1 jour)
-6.69%
Changement (1 an)
19.42%
Pays
CN
Échange HBM Holdings Limited (2142)

Catégorie

Healthcare
Historique du prix de l'action pour HBM Holdings Limited (2142)
Prix de clôture le plus élevé : $1.98 le 2026-08-01

Prix de clôture le plus bas : $1.35 le 2020-12-01
Historique du prix de l'action de HBM Holdings Limited de 2020 à 2026
Performance annuelle du prix de l'action
Année Performance
2026 (TTM) -0.88%
2025 894.28%
2024 -16.69%
2023 -21.19%
2022 -75.51%
2021 -21.32%
2020 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $548.36 39.87%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.06K 50.29%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.53 -12.48%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $140.81 475.44%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $765.25 7.74%
CH